Nasal septum perforation and bevacizumab

A 52-year-old woman, with a metastatic breast cancer, presented with a nasal septum perforation while receiving a treatment combining paclitaxel and bevacizumab. This is the fifth reported case of nasal septum perforation probably related to an anti-angiogenic therapy. A literature review and a disc...

Full description

Saved in:
Bibliographic Details
Published in:La revue de medecine interne 2011-04, Vol.32 (4), p.e43-e45
Main Authors: Bengrine-Lefevre, L, Afchain, P, Chibaudel, B, Gervais, H, Tournigand, C, De Gramont, A, Louvet, C
Format: Article
Language:fre
Subjects:
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Bevacizumab
Breast Neoplasms - complications
Breast Neoplasms - drug therapy
Breast Neoplasms - secondary
Female
Humans
Middle Aged
Nasal Septum - drug effects
Nasal Septum - pathology
Nose Diseases - chemically induced
Nose Diseases - pathology
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 52-year-old woman, with a metastatic breast cancer, presented with a nasal septum perforation while receiving a treatment combining paclitaxel and bevacizumab. This is the fifth reported case of nasal septum perforation probably related to an anti-angiogenic therapy. A literature review and a discussion concerning the different causes of nasal septum perforation were performed.
ISSN:1768-3122
DOI:10.1016/j.revmed.2010.04.015